Read by QxMD icon Read

Parkinson's and PET scan

Paul J Mattis, Martin Niethammer, Wataru Sako, Chris C Tang, Amir Nazem, Marc L Gordon, Vicky Brandt, Vijay Dhawan, David Eidelberg
OBJECTIVE: To determine whether cognitive impairment in Parkinson disease (PD) and Alzheimer disease (AD) derives from the same network pathology. METHODS: We analyzed (18)F-fluorodeoxyglucose PET scans from 40 patients with AD and 40 age-matched healthy controls from the Alzheimer's Disease Neuroimaging Initiative and scanned an additional 10 patients with AD and 10 healthy controls at The Feinstein Institute for Medical Research to derive an AD-related metabolic pattern (ADRP) analogous to our previously established PD cognition-related pattern (PDCP) and PD motor-related pattern (PDRP)...
October 5, 2016: Neurology
Sang Soo Cho, Kelly Aminian, Crystal Li, Anthony E Lang, Sylvain Houle, Antonio P Strafella
Fatigue is a common and disabling non-motor symptom in Parkinson's disease associated with a feeling of overwhelming lack of energy. The aim of this study was to identify the neural substrates that may contribute to the development of fatigue in Parkinson's disease. Twenty-three Parkinson's disease patients meeting UK Brain Bank criteria for the diagnosis of idiopathic Parkinson's disease were recruited and completed the 2-[(18) F]fluoro-2-deoxy-D-glucose (FDG)-PET scan. The metabolic activities of Parkinson's disease patients with fatigue were compared to those without fatigue using statistical parametric mapping analysis...
August 29, 2016: Human Brain Mapping
Renata P Lerner, Zisis Bimpisidis, Stergiani Agorastos, Sandra Scherrer, Stephen L Dewey, M Angela Cenci, David Eidelberg
Dissociation of vasomotor and metabolic responses to levodopa has been observed in human subjects with Parkinson's disease (PD) studied with PET and in autoradiograms from 6-hydroxydopamine (6-OHDA) rat. In both species, acute levodopa administration was associated with increases in basal ganglia cerebral blood flow (CBF) with concurrent reductions in cerebral metabolic rate (CMR) for glucose in the same brain regions. In this study, we used a novel dual-tracer microPET technique to measure CBF and CMR levodopa responses in the same animal...
August 17, 2016: Neurobiology of Disease
Ka Kit Wong, David M Raffel, Nicolaas I Bohnen, Gulchin Altinok, Sid Gilman, Kirk A Frey
OBJECTIVE: To detect regional patterns of cardiac sympathetic denervation in idiopathic Parkinson disease (IPD) using (11)C-hydroxyephedrine (HED) PET and determine the denervation rate over 2 years. BACKGROUND: In IPD, Lewy body accumulation in cardiac autonomic ganglia leads to extensive cardiac sympathetic neuronal loss, as demonstrated on (123)I-metaiodobenzylguanidine ((123)I-MIBG) imaging and in (11)C-HED and (18)F-fluorodopamine ((18)F-DA) PET. The natural history of onset and progression of cardiac sympathetic denervation has not been determined...
August 18, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Su Jin Chung, Jae Jung Lee, Jee Hyun Ham, Byoung Seok Ye, Phil Hyu Lee, Young H Sohn
BACKGROUND: The mechanism underlying non-motor symptoms in Parkinson's disease has not yet been elucidated. In this study, we hypothesized that Parkinson patients with more non-motor symptoms have a different pattern of striatal dopamine depletion, particularly in areas other than the sensorimotor striatum, compared to those with fewer non-motor symptoms. METHODS: We conducted a prospective survey of the degree of non-motor symptoms (using the Korean version of the Non-Motor Symptoms Scale; K-NMSS) in 151 patients with early-stage Parkinson's disease who had undergone a dopamine transporter PET scan as an initial diagnostic procedure...
2016: PloS One
Rizwan S Akhtar, Sharon X Xie, Laura Brennan, Michael J Pontecorvo, Howard I Hurtig, John Q Trojanowski, Daniel Weintraub, Andrew D Siderowf
BACKGROUND: Neuronal loss and α-synuclein (α-syn) pathology are diagnostic of PD in the appropriate clinical context. However, some PD patients have co-morbid Alzheimer's disease (AD) pathology on autopsy, including amyloid-β (Aβ) plaques and neurofibrillary tangles. Florbetapir((18)F) is a PET ligand that detects Aβ pathology. We hypothesized that florbetapir((18)F) imaging could detect Aβ pathology in Parkinson disease dementia (PDD) patients prior to death. OBJECTIVE: To determine the utility of florbetapir((18)F) PET imaging in detecting Aβ pathology in patients with autopsy-confirmed PDD...
July 2016: Movement Disorders Clinical Practice
Benjamin M Kandel, Brian B Avants, James C Gee, Corey T McMillan, Guray Erus, Jimit Doshi, Christos Davatzikos, David A Wolk
INTRODUCTION: Cognitive tests and nonamyloid imaging biomarkers do not consistently identify preclinical AD. The objective of this study was to evaluate whether white matter hyperintensity (WMH) volume, a cerebrovascular disease marker, is more associated with preclinical AD than conventional AD biomarkers and cognitive tests. METHODS: Elderly controls enrolled in the Alzheimer's Disease Neuroimaging Initiative (ADNI, n = 158) underwent florbetapir-PET scans, psychometric testing, neuroimaging with MRI and PET, and APOE genetic testing...
2016: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Toru Ishii, Nobukatsu Sawamoto, Hayato Tabu, Hidekazu Kawashima, Tomohisa Okada, Kaori Togashi, Ryosuke Takahashi, Hidenao Fukuyama
Patients with Parkinson's disease (PD) have been suggested to share personality traits characterised by low novelty-seeking and high harm-avoidance. Although a link between novelty-seeking and dopamine is hypothesised, the link is not fully supported by 6-[(18)F]fluoro-L-dopa positron emission tomography (PET) studies. Meanwhile, tractography studies with magnetic resonance imaging (MRI) link personality to the connectivity of the striatum in healthy subjects. Here, we investigated neurochemical and anatomical correlates of characteristic personality traits in PD...
September 2016: Journal of Neurology
Tatsuhiro Terada, Masamichi Yokokura, Etsuji Yoshikawa, Masami Futatsubashi, Satoshi Kono, Takashi Konishi, Hiroaki Miyajima, Takanori Hashizume, Yasuomi Ouchi
BACKGROUND: The neuroinflammatory glial response contributes to the degenerative process in Parkinson's disease (PD). However, the pattern of microglial progression remains unclear. METHODS: We evaluated microglial activation in early stage PD patients by quantifying changes in neuroinflammation using PET with [(11)C]DPA713, a selective PET tracer for microglial activation. Eleven PD patients (Hoehn and Yahr stages 1-2) without dementia underwent the [(11)C]DPA713 PET scan two times with 1 year apart...
October 2016: Annals of Nuclear Medicine
An Vo, Wataru Sako, Koji Fujita, Shichun Peng, Paul J Mattis, Frank M Skidmore, Yilong Ma, Aziz M Uluğ, David Eidelberg
Spatial covariance mapping can be used to identify and measure the activity of disease-related functional brain networks. While this approach has been widely used in the analysis of cerebral blood flow and metabolic PET scans, it is not clear whether it can be reliably applied to resting state functional MRI (rs-fMRI) data. In this study, we present a novel method based on independent component analysis (ICA) to characterize specific network topographies associated with Parkinson's disease (PD). Using rs-fMRI data from PD and healthy subjects, we used ICA with bootstrap resampling to identify a PD-related pattern that reliably discriminated the two groups...
May 21, 2016: Human Brain Mapping
Allan K Hansen, Karoline Knudsen, Thea P Lillethorup, Anne M Landau, Peter Parbo, Tatyana Fedorova, Hélène Audrain, Dirk Bender, Karen Østergaard, David J Brooks, Per Borghammer
The tau tangle ligand (18)F-AV-1451 ((18)F-T807) binds to neuromelanin in the midbrain, and may therefore be a measure of the pigmented dopaminergic neuronal count in the substantia nigra. Parkinson's disease is characterized by progressive loss of dopaminergic neurons. Extrapolation of post-mortem data predicts that a ∼30% decline of nigral dopamine neurons is necessary to cause motor symptoms in Parkinson's disease. Putamen dopamine terminal loss at disease onset most likely exceeds that of the nigral cell bodies and has been estimated to be of the order of 50-70%...
July 2016: Brain: a Journal of Neurology
Vikram Adhikarla, Fanxing Zeng, John R Votaw, Mark M Goodman, Jonathon A Nye
INTRODUCTION: Dysregulation of the noradrenergic system has been implicated in a number of neurological conditions such as Parkinson's and Alzheimer's. [(11)C]MENET is a novel PET radiotracer with high affinity and selectivity for the norepinephrine transporter. The applicability of different kinetic models on [(11)C]MENET PET image quantification in healthy population is evaluated. METHODS: Six healthy volunteers (mean age: 54years) were recruited for the study, five of whom underwent arterial sampling for measurement of the input function...
May 2016: Nuclear Medicine and Biology
Fiona E Parkinson, Soumen Paul, Dali Zhang, Shadreck Mzengeza, Ji Hyun Ko
2-(18) F-fluorodeoxy-D-glucose (FDG) is a glucose analog that is taken up by cells and phosphorylated. The amount of FDG accumulated by cells is a measure of the rate of glycolysis, which reflects cellular activity. As the levels and actions of the neuromodulator adenosine are dynamically regulated by neuronal activity, this study was designed to test whether endogenous adenosine affects tissue accumulation of FDG as assessed by positron emission tomography (PET) or by postmortem analysis of tissue radioactivity...
July 2016: Journal of Neuroimaging: Official Journal of the American Society of Neuroimaging
Nevein Ibrahim, Joanna Kusmirek, Aaron F Struck, John M Floberg, Scott B Perlman, Catherine Gallagher, Lance T Hall
Idiopathic Parkinson's disease (PD) is the second most common neurodegenerative disorder. Early PD may present a diagnostic challenge with broad differential diagnoses that are not associated with nigral degeneration or striatal dopamine deficiency. Therefore, the early clinical diagnosis alone may not be accurate and this reinforces the importance of functional imaging targeting the pathophysiology of the disease process. (18)F-DOPA L-6-[(18)F] fluoro-3,4-dihydroxyphenylalnine ((18)F-DOPA) is a positron emission tomography (PET) agent that measures the uptake of dopamine precursors for assessment of presynaptic dopaminergic integrity and has been shown to accurately reflect the monoaminergic disturbances in PD...
2016: American Journal of Nuclear Medicine and Molecular Imaging
Kacie D Deters, Shannon L Risacher, Karmen K Yoder, Adrian L Oblak, Frederick W Unverzagt, Jill R Murrell, Francine Epperson, Eileen F Tallman, Kimberly A Quaid, Martin R Farlow, Andrew J Saykin, Bernardino Ghetti
Gerstmann-Sträussler-Scheinker Disease (GSS) is a familial neurodegenerative disorder characterized clinically by ataxia, parkinsonism, and dementia, and neuropathologically by deposition of diffuse and amyloid plaques composed of prion protein (PrP). The purpose of this study was to evaluate if [(11)C]Pittsburgh Compound B (PiB) positron emission tomography (PET) is capable of detecting PrP-amyloid in PRNP gene carriers. Six individuals at risk for GSS and eight controls underwent [(11)C]PiB PET scans using standard methods...
2016: American Journal of Nuclear Medicine and Molecular Imaging
Grazia D Femminella, Siddharth Ninan, Rebecca Atkinson, Zhen Fan, David J Brooks, Paul Edison
BACKGROUND: The influence of neuroinflammation on neuronal function and hippocampal atrophy in Alzheimer's disease (AD) and Parkinson's disease dementia (PDD) is still unclear. OBJECTIVES: Here we investigated whether microglial activation measured by [11C]PK11195 PET is associated with neuronal function measured by cerebral glucose metabolic rate (rCMRGlc) using FDG-PET and hippocampal volume measurements. METHODS: We enrolled 25 subjects (9 PDD, 8 AD, and 8 controls) who underwent PET scans with [11C](R)PK11195, [18F]FDG, and volumetric MRI scanning...
2016: Journal of Alzheimer's Disease: JAD
Shichun Peng, Yilong Ma, Joseph Flores, Michael Cornfeldt, Branka Mitrovic, David Eidelberg, Doris J Doudet
: Abnormal covariance pattern of regional metabolism associated with Parkinson's disease (PD) is modulated by dopaminergic pharmacotherapy. Using high resolution FDG PET and network analysis we previously derived and validated a parkinsonism-related metabolic pattern (PRP) in non-human primate models of PD. It is currently not known whether this network is modulated by experimental therapeutics. In this study we examined changes in network activity by striatal implantation of human levodopa-producing retinal pigment epithelial (hRPE) cells in parkinsonian macaques and evaluated its reproducibility in a small test-retest study...
April 7, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Angelina R A Pikstra, Anouk van der Hoorn, Klaus L Leenders, Bauke M de Jong
INTRODUCTION: In this retrospective study concerning patients with Parkinson's disease (PD) scanned with 18-F-Dopa PET (N = 129), we looked for an association between reduced 18-F-Dopa uptake and the key PD symptoms tremor and hypokinesia-rigidity. We hypothesized to find a stronger correlation between dopaminergic depletion in the striatum and hypokinesia-rigidity compared to tremor. METHODS: The onset side of symptoms (documented for 102 patients) as well as the first registered UPDRS (available for 79 patients) was used to correlate with F-Dopa uptake values in the caudate nucleus and putamen in this large retrospective sample...
2016: NeuroImage: Clinical
Yi-Hua Fa, Jian-Qiang Ni, Xiao-Jin Wu, Jia-Qing Tan, Yi-Wei Wu
The aim of the present study was to investigate the use of (18)F-fallypride micro-positron emission tomography (micro-PET) imaging in the evaluation of the early therapeutic efficacy of L-dopa in the treatment of Parkinson's disease (PD) and the underlying mechanism. (18)F-fallypride was synthesized and its specific binding with dopamine (DA) receptors in normal mouse brain was studied. Following the establishment of a mouse model of PD, the animals were divided into normal control, PD model and L-dopa treatment groups...
January 2016: Experimental and Therapeutic Medicine
David J Brooks
The dopamine transporter (DAT) is responsible for clearance of dopamine from the synaptic cleft after its release. Imaging DAT availability provides a measure of dopamine terminal function and a method for detecting the striatal dopamine terminal dysfunction present in idiopathic Parkinson's disease (PD) and atypical neurodegenerative parkinsonian disorders such as multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD). DAT imaging with positron emission tomography (PET) or single photon emission computed tomography (SPECT) can be used to support or refute a diagnosis of dopamine deficient parkinsonism in cases where this is unclear and rationalise a trial of dopamine replacement agents as therapy...
September 2016: Ageing Research Reviews
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"